Stocktoria
SUTRO BIOPHARMA, INC. STRO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-09-27
SUTRO BIOPHARMA, INC. statistics & valuation
Market cap$505.7M
P / S4.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Net margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% |
| Return on assets | -109.9% | -58.7% | -22.7% | -29.3% | -30.9% |
| Return on equity | 144.3% | -510.0% | -71.4% | -54.9% | -41.8% |
| Debt / equity | — | — | 0.03× | 0.07× | 0.10× |
| Current ratio | 2.01 | 2.60 | 4.50 | 5.31 | 5.24 |
| Revenue growth | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% |
Source: SEC EDGAR filings · CIK 0001382101 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.